readthroughSign in
Nov 10, 2026Quarterly update

Atara reports Q3 2026 results as tab-cel BLA resubmission moves toward March 2027 FDA decision

The FDA has accepted Atara's resubmitted BLA for tabelecleucel in EBV+ PTLD, with a target action date of March 31, 2027, and approval would trigger a $31 million milestone from Pierre Fabre.

Atara Biotherapeutics reported third quarter 2026 financial results and business updates on November 10, 2026. The company's lead update concerned tabelecleucel (tab-cel, also known as EBVALLO), its therapy for Epstein-Barr virus positive post-transplant lymphoproliferative disease. The FDA has accepted the Biologics License Application resubmission for tabelecleucel, proposed as monotherapy for adult and pediatric patients two years of age and older with EBV+ PTLD who have received at least one prior therapy.1 The resubmission carries a Class 2 Resubmission PDUFA target action date of March 31, 2027.1

If the FDA approves tabelecleucel, Atara would be eligible for a $31 million milestone payment under its commercialization agreement with Pierre Fabre Laboratories, along with double-digit tiered royalties on net sales and additional milestones tied to commercial sales of EBVALLO.1 CEO Cokey Nguyen said the resubmission was an important milestone this quarter, and that Atara remains focused on supporting Pierre Fabre Pharmaceuticals toward a successful outcome.1

On financial position, cash, cash equivalents and short-term investments as of September 30, 2026 totaled $9.9 million, unchanged from $9.9 million as of June 30, 2026.1 The company said this cash position, combined with operating efficiencies achieved in 2025 and the first half of 2026, is expected to be sufficient to fund planned operations into mid-2027.1

The filing also flagged regulatory risk tied to the resubmission. In its risk disclosures, Atara noted uncertainty over whether the resubmitted filing adequately resolves concerns raised in the Complete Response Letter the company received on January 9, 2026, among other issues the FDA could raise during review. The filing further noted that Pierre Fabre Pharmaceuticals, not Atara, holds the tab-cel BLA and controls the content and strategy of the application and related FDA interactions, limiting Atara's ability to influence the review process.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.